Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195602 | 1.00 | DRD4 (0.54) | DRD4PDK1HRH3HSD17B10 | |
| SCHEMBL3187766 | 0.87 | HRH3 (0.63) | DRD4PDK1HRH3 | |
| SCHEMBL3187777 | 0.87 | HRH3 (0.63) | DRD4PDK1HRH3 | |
| Hydrochloric Acid SCHEMBL25394023 | 0.86 | HRH3 (0.62) | DRD4PDK1HRH3 | |
| Hydrochloric Acid SCHEMBL25394018 | 0.86 | HRH3 (0.62) | DRD4PDK1HRH3 | |
| SCHEMBL3182030 | 0.85 | PDK1 (0.53) | DRD4PDK1HRH3 | |
| SCHEMBL29877195 | 0.85 | ALDH1A1 (0.54) | DRD4PDK1HRH3 | |
| SCHEMBL3182045 | 0.85 | PDK1 (0.53) | DRD4PDK1HRH3 | |
| SCHEMBL17823745 | 0.85 | PDK1 (0.49) | DRD4PDK1HRH3 | |
| SCHEMBL971720 | 0.85 | PDK1 (0.49) | DRD4PDK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| CN-1950348-A | Substituted morpholino compounds for the treatment of central nervous system disorders | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | DRD4 105/4885PDK1 4096/4885HRH3 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.